Weiss Ratings Reiterates "Sell (D-)" Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report)'s stock had its "sell (d-)" rating reissued by investment analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

Several other equities analysts also recently issued reports on FDMT. The Goldman Sachs Group dropped their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Chardan Capital reissued a "buy" rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, July 3rd. Finally, Barclays decreased their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $29.56.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $4.28 on Friday. The company has a market cap of $198.29 million, a PE ratio of -1.35 and a beta of 2.81. The firm has a 50-day moving average of $3.86 and a 200-day moving average of $4.14. 4D Molecular Therapeutics has a one year low of $2.24 and a one year high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. Analysts expect that 4D Molecular Therapeutics will post -2.84 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in 4D Molecular Therapeutics in the 4th quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in 4D Molecular Therapeutics in the 4th quarter worth $50,000. PNC Financial Services Group Inc. lifted its stake in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after purchasing an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its stake in 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock worth $55,000 after purchasing an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new stake in 4D Molecular Therapeutics in the 4th quarter worth $56,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.